PENUT Trial: Preterm Epo Neuroprotection

PENUT Trial - Preterm Epo Neuroprotection

Mission: To improve the health and well being of premature babies

The PENUT Trial is a randomized, multi-center, placebo-controlled trial designed to test the efficacy of erythropoietin (Epo) for the neuroprotection of extremely premature infants


The aim of this NINDS funded trial is to assess whether early high dose Epo will improve survival without neurodevelopmental impairment (NDI) in infants born between 24 and 28 weeks of gestation. 940 preterm infants will be enrolled at 19 centers across the U.S. Infants will be assessed at 2 years of age to see whether Epo treatment improved neurodevelopmental outcomes.

Principal Investigator, Clinical Coordinating Center: Sandra Juul, MD, PhD
Principal Investigator, Data Coordinating Center: Patrick Heagerty, PhD
Funding: NINDS 1U01NS077953-01 Identifier: NCT01378273